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National intelligence network on drug 
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Published December 2020 
This briefing is based on the latest meeting of the national intelligence network (NIN) on 
the health harms associated with drug use. It includes topics covered at the October 
meeting and has been updated with the latest information in each case. 
The NIN is made up of representatives from drug treatment services, local authority public 
health and commissioning teams and national professional and membership bodies. 
Network meetings are chaired by Dr Michael Kelleher, consultant addictions specialist and 
clinical lead for Lambeth Addictions at the South London and Maudsley NHS Foundation 
Trust. 
The future of public health and PHE 
The government has published its plans for creating a National Institute for Health 
Protection. Options for future arrangements for health improvement and other Public 
Health England (PHE) functions are also being considered. 
COVID-19 
PHE’s COVID-19 guidance for drugs and alcohol covers national restrictions. Refer to 
local and specific guidance on GOV.UK for additional local, tiered restrictions. 
PHE is encouraging services to bring back face-to-face interventions where it is safe and 
appropriate. This should include increasing hepatitis C testing and treatment, resuming 
hepatitis B vaccination schedules, where they have been interrupted and reviewing opioid 
substitution treatment (OST) dispensing arrangements. 
The GOV.UK personal protective equipment (PPE) portal is now open to all drug and 
alcohol providers: residential and community. The portal is able to meet all COVID-19 
need, not just urgent (but not business-as-usual need). 
Regular, repeat COVID-19 testing of staff and residents is now available to residential 
services. 
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Dame Carol Black independent review of drugs 
A second stage report of Dame Carol Black’s independent review of drugs will make 
recommendations to the government about what drug treatment and recovery 
commissioning and accountability mechanisms should be put in place. There will also be 
recommendations on prevention and treatment services for young people. 
Project ADDER 
Project ADDER is a cross-government project led by the Home Office which will test a 
whole-system approach to tackling drug use in parts of the UK with high levels of drug-
related deaths. The project will involve coordinated law enforcement, diversionary and 
enhanced treatment and recovery provision. This will be complemented by National Crime 
Agency activity to tackle middle market drugs and firearms supply. 
PHE has been working closely with other government departments and the local authority 
areas involved to produce evidence-based packages of outreach, diversionary, harm 
reduction, treatment and recovery interventions tailored to local need. These include 
assertive outreach and engagement teams and widening naloxone provision, including 
distribution by peers and police. 
Opioid substitution treatment good practice programme 
PHE’s OST good practice programme, which aims to support improvements in the quality 
of OST in England, will publish some resources in the coming months. These will include: 
• a report outlining the key issues impacting on the quality of OST in England
• an OST service self-assessment tool
• an OST guide for drug treatment and recovery workers
• OST-focused e-learning for drug treatment and recovery workers
The e-learning, which includes films following 2 characters who are on OST, aims to 
support frontline drug treatment and recovery workers to have more evidence-based 
conversations about OST. This will help make sure service users get the information, 
advice and support they need to get the most out of OST. 
Alerts activity 
In July PHE issued a national alert about illicit benzodiazepines that are being sold and 
packaged as legitimate products. Overdoses, hospitalisations and deaths caused by these 
drugs have continued over recent months and PHE is monitoring, assessing and 
responding. 
Most recently pills in the South West of England marked ‘DAN 5260’ have been found to 
contain clonazolam and tablets marked ‘C/DC’ have been found to contain flubromazolam 
(both potent benzodiazepine analogues). ‘DAN 5260’ pills were also implicated in a recent 
death. Toxicology on 4 deaths across one area, again in the South West, showed 
phenazepam (a powerful benzodiazepine) was present, along with other substances. 
Recent deaths among students in Newcastle and nearby Washington have highlighted the 
risks that students face during the COVID-19 pandemic. 
3 
‘Nerds Rope’ sweets containing THC are being sold online and in shops (in Yorkshire and 
the Humber and the North West) and have been linked to hospitalisations in London. It is 
not clear whether these products have been imported from the USA, where they are widely 
available, or produced in England, perhaps with varying amounts of THC or other drugs. 
As well as routine drug surveillance activity, PHE has been working with organisations like 
the Welsh Emerging Drugs & Identification of Novel Substances Project (WEDINOS) and 
the charity Release to monitor changes in the drug market and drug use during lockdown. 
You can share intelligence on drug markets and harms with drug.alerts@phe.gov.uk. 
European Drug Report (Alberto Oteo, UK Focal Point) 
Launched in September, the 2020 European Drug Report shows increases in cocaine use 
across Europe. The report also highlights large seizures across the continent which 
suggest there has been increased heroin use. 
Overall there is growing complexity in the drug market in Europe. Increased quantities of 
GHB, ketamine and LSD have been seized recently. Concerns have been raised by some 
countries about the use of non-controlled or new benzodiazepines, and nitrous oxide. 
In 2017 to 2018, hepatitis C virus antibody prevalence in national samples of people who 
inject drugs ranged from 16% to 86%, with 10 of the 16 countries having national reported 
rates of more than 50%. 
Findings from Living Under COVID-19 and Injecting Drugs in Bristol (LUCID-B) (Dr 
Lindsey Hines, University of Bristol) 
Vulnerable groups are disproportionately affected by the pandemic and the impact of 
lockdowns and social distancing. The Living Under COVID-19 and Injecting Drugs in 
Bristol (LUCID-B) research study interviewed 28 people who inject drugs (mostly receiving 
opioid substitution treatment, and many in emergency housing) about their experiences in 
Bristol. 
Interviewees said that temporary accommodation was isolating and negatively affected 
their mental health. Stressors included drug use by other residents, and eviction fears. For 
a few, the isolation did not differ from their pre-pandemic lives. 
Participants said they wanted structure, activities, and drug use support. Some people 
housed in the government scheme had received more support from health services than 
before the pandemic. 
In the initial phase of responding to the pandemic, drug treatment services transferred 
most patients from supervised consumption to take-home doses of OST medicines. Most 
people interviewed reacted positively to the change, with some reporting self-adjusting 
their dose to suit their needs. 
Many participants were less comfortable receiving support over the phone or internet, and 
lack of internet access hindered access for a few. 
Participants were happy to discuss access to treatment and other healthcare with drug 
service outreach staff. 
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Impact of the COVID-19 pandemic on prevention, testing and care for hepatitis C 
(Sema Mandal, PHE National Infection Service) 
Provisional analysis of surveillance data from NHS laboratories between March and 
August shows a decline in hepatitis C testing, diagnoses and treatment initiation in all 
settings. There is evidence that the COVID-19 pandemic response, including social 
distancing, led to a de-prioritisation of, and disruption to, health services for hepatitis. 
While there is some evidence that hepatitis C diagnoses and treatment initiations 
increased in the summer this is less pronounced in drug services. 
